Narrative review / 2013
A review discusses how obesity, type 2 diabetes, insulin, and insulin-like growth factors are involved in increased cancer risk and progression.
This narrative review examines the molecular basis linking obesity, type 2 diabetes, and cancer. Epidemiological and biochemical evidence indicates that morbidly high levels of endogenous or therapeutic insulin, hyperinsulinaemia, and adipose-secreted insulin-like growth factors (IGF-1 and IGF-2) play key roles in cancer risk and progression. Structural insights explain how insulin, IGF-1, and IGF-2 interact with insulin and IGF receptors to drive diabetes-associated cancer, highlighting potential drug targets.
- Study type
- Narrative review
- Who was studied
- Individuals with obesity, type 2 diabetes, or diabetes-associated cancer
- What was measured
- Cancer risk and progression linked to obesity, insulin, and IGFs
THE PAPER
A twenty-first century cancer epidemic caused by obesity: the involvement of insulin, diabetes, and insulin-like growth factors.
Westley RL, May FE. Int J Endocrinol, 2013.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.